US Patent Issued to Jiangnan University on Jan. 27 for "Use of polaprezinc in preparing drug for treating castration-resistant prostate cancer" (Chinese Inventors)

ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,533,361, issued on Jan. 27, was assigned to Jiangnan University (Wuxi, China).

"Use of polaprezinc in preparing drug for treating castration-resistant prostate cancer" was invented by Rong Wang (Wuxi, China), Yongquan Chen (Wuxi, China), Shenglong Zhu (Wuxi, China), Xiaoying Wang (Wuxi, China), Yuanyuan Mi (Wuxi, China), Sheng Wu (Wuxi, China) and Jian Sun (Wuxi, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure discloses use of polaprezinc (Pola) in preparing a drug for treating castration-resistant prostate cancer (CRPC) and belongs to the technical field of biological medicine. The present disclosure provides a new strategy ...